Blue Trust Inc. Reduces Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Blue Trust Inc. decreased its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCTFree Report) by 12.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,872 shares of the company’s stock after selling 569 shares during the period. Blue Trust Inc.’s holdings in PROCEPT BioRobotics were worth $310,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of PRCT. Raleigh Capital Management Inc. purchased a new stake in shares of PROCEPT BioRobotics in the fourth quarter worth $32,000. SG Americas Securities LLC lifted its position in PROCEPT BioRobotics by 295.8% during the fourth quarter. SG Americas Securities LLC now owns 6,598 shares of the company’s stock valued at $531,000 after purchasing an additional 4,931 shares during the last quarter. Enclave Advisors LLC increased its holdings in shares of PROCEPT BioRobotics by 5.3% in the 4th quarter. Enclave Advisors LLC now owns 29,568 shares of the company’s stock worth $2,381,000 after buying an additional 1,499 shares during the last quarter. Perpetual Ltd purchased a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at $66,972,000. Finally, Oak Ridge Investments LLC lifted its holdings in shares of PROCEPT BioRobotics by 24.0% during the 4th quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company’s stock worth $2,420,000 after acquiring an additional 5,817 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock opened at $72.50 on Monday. PROCEPT BioRobotics Co. has a fifty-two week low of $45.20 and a fifty-two week high of $103.81. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -37.18 and a beta of 1.05. The stock’s 50 day simple moving average is $84.45 and its two-hundred day simple moving average is $79.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Jefferies Financial Group started coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a “hold” rating and a $95.00 target price for the company. Wells Fargo & Company reissued an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. Morgan Stanley initiated coverage on PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price target on the stock. Finally, Truist Financial reiterated a “buy” rating and issued a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $97.86.

Read Our Latest Analysis on PROCEPT BioRobotics

Insider Buying and Selling

In related news, EVP Alaleh Nouri sold 28,092 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the sale, the executive vice president now owns 52,472 shares in the company, valued at $5,096,605.36. This represents a 34.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Reza Zadno sold 26,420 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $92.57, for a total value of $2,445,699.40. Following the completion of the sale, the chief executive officer now directly owns 205,605 shares in the company, valued at $19,032,854.85. This trade represents a 11.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,355 shares of company stock valued at $16,758,848 over the last ninety days. Company insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Company Profile

(Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Read More

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCTFree Report).

Institutional Ownership by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.